       Document 0388
 DOCN  M9610388
 TI    Intravitreous and plasma concentrations of ganciclovir and foscarnet
       after intravenous therapy in patients with AIDS and cytomegalovirus
       retinitis.
 DT    9601
 AU    Arevalo JF; Gonzalez C; Capparelli EV; Kirsch LS; Garcia RF; Quiceno JI;
       Connor JD; Gambertoglio J; Bergeron-Lynn G; Freeman WR; Department of
       Ophthalmology, University of California, San Diego; 92093, USA.
 SO    J Infect Dis. 1995 Oct;172(4):951-6. Unique Identifier : AIDSLINE
       MED/96029360
 AB    This study evaluated intravitreous and plasma ganciclovir and foscarnet
       concentrations after intravenous administration in AIDS patients with
       cytomegalovirus (CMV) retinitis and retinal detachment. Undiluted
       vitreous samples were prospectively obtained from 60 eyes (52 patients)
       at the time of pars plana vitrectomy. Thirty-three plasma samples (from
       27 patients in the initial group of 52) were obtained simultaneously
       during surgery on 33 eyes. High-pressure liquid chromatography showed
       the mean vitreous ganciclovir concentrations in patients on induction
       and maintenance therapy were, respectively, 4.74 +/- 1.49 microM (n =
       24) and 3.29 +/- 1.84 microM (n = 30; P = .005). Simultaneous plasma
       ganciclovir concentrations were less than the vitreous concentrations in
       78% of the patients. The mean intravitreous foscarnet concentrations in
       patients receiving induction dosages were 189 +/- 177 microM (n = 5)
       versus 163 +/- 167 microM (n = 4; P > .20) for those receiving
       maintenance therapy. The foscarnet vitreous plasma concentration ratio
       averaged 1.43. Current drugs and doses for CMV retinitis result in
       borderline or progressively subtherapeutic concentrations.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG THERAPY  Adult
       Cytomegalovirus Retinitis/COMPLICATIONS/*DRUG THERAPY  Drug Therapy,
       Combination  Female  Foscarnet/BLOOD/*PHARMACOKINETICS
       Ganciclovir/BLOOD/*PHARMACOKINETICS  Human  Injections, Intravenous
       Male  Middle Age  Prospective Studies  Retinal
       Detachment/COMPLICATIONS/*DRUG THERAPY  Support, Non-U.S. Gov't
       Support, U.S. Gov't, P.H.S.  Vitreous Body/*METABOLISM  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

